ondansetron has been researched along with Acute Myelogenous Leukemia in 7 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors compared 2 schedules of palonosetron versus ondansetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) in patients with AML receiving high-dose cytarabine." | 9.14 | Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. ( Bekele, BN; Blamble, DA; Borthakur, G; Cabanillas, M; Cortes, JE; Kantarjian, H; Mattiuzzi, GN; O'Brien, S; Xiao, L, 2010) |
| "One hundred sixteen cases of leukemia patients received supra-high single dose TBI for bone marrow transplantation (BMT) with total a radiation dosage of 700-770 Gy at about 5cGy/min." | 6.68 | [Ondansetron in the prophylaxis of acute emesis induced by supra-high single dose total body irradiation (TBI)]. ( Fan, Y; Guo, N; Huang, X, 1995) |
| "The authors compared 2 schedules of palonosetron versus ondansetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) in patients with AML receiving high-dose cytarabine." | 5.14 | Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. ( Bekele, BN; Blamble, DA; Borthakur, G; Cabanillas, M; Cortes, JE; Kantarjian, H; Mattiuzzi, GN; O'Brien, S; Xiao, L, 2010) |
| "One hundred sixteen cases of leukemia patients received supra-high single dose TBI for bone marrow transplantation (BMT) with total a radiation dosage of 700-770 Gy at about 5cGy/min." | 2.68 | [Ondansetron in the prophylaxis of acute emesis induced by supra-high single dose total body irradiation (TBI)]. ( Fan, Y; Guo, N; Huang, X, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, H | 1 |
| Yin, JY | 1 |
| Xu, YJ | 1 |
| Li, X | 1 |
| Zhang, Y | 1 |
| Liu, ZG | 1 |
| Zhou, F | 1 |
| Zhai, M | 1 |
| Li, Y | 1 |
| Li, XP | 1 |
| Wang, Y | 1 |
| Zhou, HH | 1 |
| Liu, ZQ | 1 |
| Mattiuzzi, GN | 1 |
| Cortes, JE | 1 |
| Blamble, DA | 1 |
| Bekele, BN | 1 |
| Xiao, L | 1 |
| Cabanillas, M | 1 |
| Borthakur, G | 1 |
| O'Brien, S | 1 |
| Kantarjian, H | 1 |
| Huang, X | 1 |
| Guo, N | 1 |
| Fan, Y | 1 |
| Colquhoun, JP | 1 |
| Krstenansky, PM | 1 |
| Petree, J | 1 |
| Long, G | 1 |
| Sundström, GM | 1 |
| Wahlin, A | 1 |
| Yano, K | 1 |
| Matsui, H | 1 |
| Fujisawa, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.[NCT03606369] | Phase 2/Phase 3 | 560 participants (Anticipated) | Interventional | 2015-11-05 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for ondansetron and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administr | 2010 |
[Ondansetron in the prophylaxis of acute emesis induced by supra-high single dose total body irradiation (TBI)].
Topics: Adult; Female; Humans; Leukemia, Myeloid, Acute; Male; Nausea; Ondansetron; Precursor Cell Lymphobla | 1995 |
Comparison of efficacies of ondansetron and dixyrazine for prophylaxis of emesis during induction treatment in acute myelogenous leukemia. A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Amsacrine; Antiemetics; Antineoplastic Combined Chemotherapy Protoco | 1997 |
4 other studies available for ondansetron and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Alleles; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2014 |
The mark of Zorro.
Topics: Acyclovir; Aged; Anecdotes as Topic; Family Practice; Female; Herpes Zoster Oticus; Humans; Leukemia | 1994 |
Extrapyramidal reaction caused by ondansetron.
Topics: Adult; Basal Ganglia Diseases; Humans; Leukemia, Myeloid, Acute; Lorazepam; Male; Ondansetron | 1994 |
[Oral administration of cytarabine ocfosfate and ondansetron hydrochloride in patients with acute myeloid leukemia who can not be treated with intensive chemotherapy:--attempt to make their quality of life better].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Arabinonucleotides; Cytidine Monophosphate; Drug Ad | 1998 |